Q4 2019 Earnings Call
[music].
Greetings and welcome to translate reports 20 of our team urine financial results and corporate update conference call. At this time, all participants really listen only mode.
Question answer session will follow the formal presentation.
Depending what car operator systems. Please press star you're on your telephone keypad.
My pleasure to introduce your host they'll be I come down. Please go ahead.
Thank you good morning, everyone and thank you for joining us on Gen. That's full year 2019 financial results and corporate update conference call last night, we issued a press release would be updated 2019 financial figures and corporate update which can be accessed on our website at IR that genfit dot com.
I have to be getting I would like to note that during our call we'll be making forward looking statement.
Webcast contain certain forward looking statements as defined under the private Securities Litigation Reform Act of 1995 with respect to junket are expected future performance isn't this prospect financial guidance, that's our plan, including timing of the announcement of the topline interim results of our eighth.
Resolve it clinical trial timing of our NDA submission for elephant, Bernard Nash tightening of clinical and regulatory milestones regulatory and developmental timeline for our niche for technology and its availability as an L.D. beyond the clinical research environment, and our ability to continue supporting activities and to minimize.
Central to lead our business once the covert 19 pandemic subside.
These forward looking statements are based on assumptions and estimates by management, which although believed to be reasonable are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in or implied or projected by the forward looking statements. These forward looking statements you only.
As of the date of this webcast other than as required by applicable law a comedy does not undertake any obligation to update or revise any forward looking information or statement, whether as a result of new information future events or otherwise.
Following the prepared remarks, well open up the call for approximately 20 minutes of question that will be addressed by Genfit management, Peskov Pujol, CEO, Dean Hum COO and Carl I'd see ammo. Please limit yourself to one initial question to allow time for other question I now turn the call over to our CEO Pascal crucial.
Thank you know me.
Thank you everyone and thank people joining between you're doing a 19% will result in school boards, but did come from school, especially under the accounting circumstances.
Yes, [laughter] best you would be more worried because if you change anything we should still Jim.
You can put forth bugs goals that we achieved the greatest one that's going to truly Dolby Trokel mush almost.
<unk> a good contribute communicated the you have made 20 twond movies, because weve increases is built on these calls.
I'd be good relating to new system is going great 19 specific.
Viruses impacted those awards and puts us in ways and we didn't Genesis train called to remain as John noted to adopt was always innovation of the health and safety when we go through each of you.
In practices to secure safety approximately equal to oil price they ship.
These chemicals have changed the way you hopefully organization and that'd be Mendez Kuwaiti solution. It yes, we remain focused on public deal team and preserving business continued <unk> list. We remain on track video for both my skin Zix done for both with and possible given the circumstances with schools.
I wasn't the best fuel you had made significant changes to refocus truck true executive team and go from there.
But for example, we transition from these lives not organization to a commercial.
I guess it begins with my own just few people engine.
We're going in 18 like drilling as executive Vice President marketing and commercial.
There's about a year later, well December realism, and teams and the company's 20, if you're in good trees.
No I was appointed through all this field and he said, there's a former CEO and chairman, resulting from the objective or so forth with me today could foods acquisition as chairman of the gold.
You talked before you keep only makes area and I understand there's going to each he was a significant near still nice stone as potential in a few bundle could bring to the Nash market.
Yeah, what you'd be TV and either late stage companies such a justice has allowed me to build on the strong foundation creatures does referenceable and stuff refraining from future commercial strategy and launch plan beginning with your involving a few minutes for them.
Internal promotion.
[laughter] anything team or global headcount grew from one of those 48.
294 employees, who called market access Coffees Asian Medical affairs, and someone could lead to them.
Oh key areas that are involved can use the shift towards the more mature pulpwood and commercial structure.
We also have your kids exports. So chose looks okay and that he is joined as Chief Medical Officer, you know kind of their Jefferies.
Joel use them and get to know just by training and she brings over 20 years of experience.
Today. He these in a busy they are gonna be compressed is actually one of joint development for me coverage and chronic diseases.
So we believe she can they deal admission to aid in the deal Delta from watch football.
Yeah. So how do you did join in view of they booked as being home old feel for many years that has got I think most of you know and Ah Videophone said President Phil said Gulp a you recently relocated to East goes you know based other for Jim could called headquarters open cabbage.
In addition, we recognized achievement will move in and we promoted with kids to New York Man to head of global diagnostics needing to go with king or the baby and focus on.
So all of these changes will fall off of their multi pronged approach and then I'm going to try to achieve transition junkets form beating that strictly French based company to a more global once we get stronger U.S. would put it.
It doesn't matter of fact, we know what can be helpful. Thank you could 15, but these are true Europe.
So you could bring was further strengthen waste successful USA peel that back last year.
Mr. Bush Onexton less back when we open up opportunities from a financial perspective, Weve inclusion or you and specialized healthcare investors evolved to a lions result, positioning as Liberals down here in mesh and overusing.
Entering a phase has been weaker than netback improved visibility the U.S. in particular.
Yes, I tried to life can go tell them, we need to fill the strengthening of the team.
They chose to focus my opening remarks, a whole team genfuel human capital because their education and depth, but just avail themselves of what's going to you, but even more so.
By the challenges. So just few near term circumstances of kind of maintaining that make a difference.
And ultimately they will be the one is making for people who could easily oh solution to device based units to use and let me come.
So there's no spoke about the noble noninvasive diagnostic programs and new technology useful.
It's too late in the main team has made substantial progress from both the clinical and regulatory perspective.
As a reminder for people with French language diagnosed in stage Nash is when you go biopsy.
As you all know come in baby is closely to see deal, but maybe associated with 40 year old complication in but only a limited number of competition is can older conduct overview. So we'll realize better as he noticed chemical option.
Given the president of the decision and the highest number or suspected station neither everybody's aeration noninvasive diagnostic solution, but she made of Tonight for meeting Nash still remains a high unmet needs.
Because I haven't biomarker discovery as the time of our phase to be gogan favor five Trialing Nash just country Tonight, you need for noninvasive diagnostic stuff and you look at lease role. He told my boyfriend capable of identifying actual risk Nash patient for patients that should be treated its 50 50, specifically basis.
And Nash with significant fibrosis, but they don't full biomarker panel.
Additionally, we century search present cities November as April 2019 demonstrated that neutral was also able to outperform over noninvasive diagnostics.
The same Nash recycles is in people with type two diabetes, which we know its independent Ria nor moving through the system.
One recycler and drives our next disease progression.
Indeed, they actually expand on the late breaker present for the April These 2018 ventured robust performance across multiple clinical simplification.
Let me highlight.
But we thought as the Mississippi, we accrue to identify the patient population was a higher risk because this is production capability that will be critical for against the same station.
Potentially benefit from pharmacotherapy.
Provide healthcare professional users to solve a significant challenge in the current and future commercialization of finish rocky.
For the neutral program of them towards commercialization in January last year, when density signed or licensing partnership with Labcorp call them for implementation of neutral in the clinical research luxury network.
Well then domain name team neutral was launched globally. They called US in just a few launch it has employed to motivate sponsors for use in domestic nickel result on programs.
Even in this context, it's always been utilized to help these patients today identification and recruitment.
Different Nash clinical trial is also being explored as a maturing technology to assess patient response to therapy.
We believe that mix role will ultimately lead to substantial cost savings to try to sponsors and we also immunized unnecessary home to patients by eliminating diet season patients into of movies, this stability and growth, which is likely to be eligible for clinical trials.
We are eager to expedite and this will access and you're working on new Joe truck commercial strategy.
We are exploring opportunities to enable further licensing to support central lab partner launch of from this fall at the laboratory developed tests will also known as the end with GE.
In parallel we are also actively pursuing formal approval through to regulatory body submissions.
Yes, and human capabilities to seek approval of is in vitro diagnostic HBV.
Which is a different version of this fourth quarters pool anticipate to file is the first half of 2021.
So even in times levered caused significant because the way excluding that a few on all our lead asset which is if you buy assets at the economics for both primarily by already contemplated for PBC any match.
QVC program has shown great potential demonstrating statistically significant phase two results in these days are as we provided.
They have provided early confirmation of the efficacy endpoints use for regulatory approval that was presented that Eagle 19.
And we have to bundle and PDC consistently showed robust improvement on markers of cholestasis and metabolism reduction in inflammation as those decreasing by us is purposes.
These promising results also encouraging.
No. It's not codes also embroiled in fact of to ensure that potentially meaningful trend improving provider as measured by FDA coal.
He said he could be profile in conjunction with favorable safety and Tolerability profile ice release bar Infogenesis and BPVC could you give the whole and will become friends in the phase three trial, Oxford.
If you want to also be dresses breakthrough therapy designation by the yen and orphan drug designation by both the FDA and then showcasing the agencies recognition of the potential of 50 level.
We strongly believe that very significant unmet medical need in PBC and therefore, we are committed to give looking if you don't know for this indication.
That being said, we outgrowth favor and just look norm.
If you will not be Nash.
In 219, and if you don't know continue to show consistent and favorable safety and for RBC Bofa.
Overall for 2019 to get them be performs a 36 month and a 42 month review of resulted of much free clinical trial.
And then we can ended the continuation of the city without any modification taking into consideration safety data of patients will receive choice for for years.
So looking back over 2000 patient yields a safety data on that if you don't know automobiles achieved in particular since he has been everything question, we actually no issue of interpret databases, which I guess, it's related to the distinctions between different types of people agonist.
We believe the set aside from 50 profile of in a few or no highlights. The we work with opportunities for everybody else potential use that you watch indeed, innovating asylum disease like Nash side effects could negatively impact complex.
And can you smell she's associated with increased cardiovascular risk we feel is relevant with his best trials and if you run was actually consistency who founded the child as we won't see insulin resistance or get to rise or exit.
So thanks with stable efficacy and safety profile density is actually the first company to initiate a kidney.
And then evaluate that if you don't know as the potential for IP for pediatric patients with much.
Aside from the phase three development Dinesh gentry continues to explore overall production line, though in multiple clinical programs, including the commissions to be okay. If you don't always GLP, one agonist Sps to leaders in their seasonal impact on particularly good competition on patient weaknesses.
To give it a name team was also euro where we made significant progress under commercial from.
The first we signed a very meaningful partnership with the licensing of for commercialization right. After the feeble north for Nash and PTC in greater China lease terms pharmaceuticals.
Aside from the financial benefit from this agreement, where we secured the finished slightly lower upfront payments with potential upside north of a 93 million based on milestone. This about you see also incorporates an exciting R&D collaborations for individual and commission assets targeting match. These studies will be discussed.
As the programs materialize.
We don't commercial commercialization strategy for greater China sluggish. We also have allocated considerable amount of time and time to.
To us and new market access plan.
In preparation for the commercial launch density is not clear our approach of the Bhavan gate based on a rigorous for your research.
While finding highlight that the yields anticipate including natural piece of the formularies regardless of endpoint.
And the main contingencies around price spot.
Joining me on the findings indicate the benefits you're requirements will be dependent on price was an option to pay for access to the mobile world. These prices driven evolves. The majority of sales are not currently contemplating both through requirement.
We also learn helicopter definitively profile is seen as meaningful from a significant number for years and healthcare professionals, you don't grow a notification that awareness building remains to be done internet space.
We continue to develop the pricing strategy that we hope will enable an unfunded access for potential patients.
While driving tangible value for shareholders.
Additional energy and resources as exhibited towards for greater launch capacity, including regardless of medical science liaison team for scientific information. This information as these team will be deployment in 2020.
We also worked on the contained for HCP than patients for lunch connected civil HCP and they are vital to go meaning and build educational awareness packages for both in a few bono and control.
So looking forward to 2020, and I guess with must anticipate a dead rebuilt the Brazil.
We expect to announce featuring results of our results to the by the end of May 2020.
And.
Next month central facial recall, our previous guidance from February we were about to lock the database, which we are waiting as good feedback to unblind the trial.
So we weren't debating it if you buy making as much.
These announcements of top line results for two weeks ago. So we all we know we did local elevates us down at the end of February and we're very happy to phase, but we just got the feedback. So we actually very thankful that would trend situation did not have a material impact on the timeline.
So we all know abating the study protocol and statistical analysis plan based on these recommendation and of course that means that at this stage, we remain blinded to the data.
We are working closely we won't see our role as we are escalating all processors as quickly as possible to incorporate the feedback.
But of course, no need to adjust to quality leads us to another and most importantly, though form necessarily QC and validation and over checks and balances.
Of course, the three main seem to make is not making the work across your different teams involved in media.
Hi, everybody involved and what has been giving us a beginning heavier than 10% and we feel confident we will be in a position to announce top line results by management.
As a reminder, essentially revolving study.
Was initiated in 2016.
As the leading the efficacy and safety us with if you don't often and 12 milligram versus placebo in patients with national voters to trials. The 72 week multi center randomized double blind placebo controlled study and the data read out because it is of course will be system is supportive of submitting an IND.
For approval and disrupt our age in the U.S. and conditional approval in Europe.
If successful this could be for first and only pivotal phase three trial to achieve Nash resolution, we'd like to worsening of high voltage standpoint, addressing the underlying growth of national digital Russia.
So we are hopeful for confirmation of his expectation.
As previously communicated.
And as recorded 19 funding continues to unfold.
Team as they can also portion by closing the initiation of new studies improved ongoing phase one phase two clinical trials on the whole, including those supportive of NFC by now in the Nash.
I mean, obviously unclear at this stage wins included 19 pending equally subside and therefore revenue will be able to reduce of efforts.
Which is why we are gaining alford CMBS submission for energy behind Nash.
Expected to close the first half of 2021.
However, the company continues to remain steadfast in price all associated regulatory review, leading up to that planning as well as launch readiness initiatives.
The extension phase of Brazil, with four clinical outcome remains ongoing aside from if she adjustments to protect patient safety in light of recruitment in 10 minutes.
In all additional clinical support functions continue to progress in an effort to limit industrials interruptions when determining crisis site.
And to conclude briefly addressing our financial.
Cash equivalent the marketable securities Gentiva and free cash position of 267 million Euro as of December 31st and then Tim.
Yes, it's 207 million as the end of 2018. So this increase obviously can be healthy attributed to a successful global financing in USA IPO in March 2019, which raised gross proceeds of 150 tracking doors.
And the $35 million upon settlement they buy from some difficult to Genset in July 19th.
Just anticipate that expenditures in 2020 wells trendy depend obviously, that's the nature of the topline results from both of.
The trick nickel trial, which remain a known as of today.
And for detailed overview of operating results for the period ending in December.
Team I refer you to our press release that we issued yesterday.
So I'd like now to turn to can also on to the appraisal for FY QNX session.
Operator.
Thank you an absolute ducking your question answer session, if you'd like to replacing the question too. Please press star one or telephone keypad, a confirmation code will indicate your line is in the question Q.
Chris start to if you'd like to remove your question for the Q.
Participants using speaker quit maybe be necessary to pick up or headset before pressing the star keys. Once again that star one to replace the question Q1 moment. Please while we pull for questions. Our first question today is coming from common Smith from SVB Leerink. Your line is no lives.
Hey, guys. Thanks for taking the questions.
First I was hoping you could provide a little more detail around the key secondary endpoint youve elevated and resolve it related to the changes and metabolic parameters can you just give us a little more color on what specifically are measuring here and what type of feedback was provided in the recent FDA communication.
Okay.
Hi, Tom.
Thanks for coming for the question.
So really the additional key secondary endpoints.
The which we have now we're actually part of our preliminary interest elevated saving two key signals and those are on on point.
To be cognizant that will comment, though because old you ways because.
Much patients as at a particular cardiovascular risk and because Nash.
Metabolic disease it was.
Really important information for on potential prescribers of methanol.
Q2 health for advanced formation in retail.
Considerably we would have stronger data as of course, we control for four yes.
So those those.
Peter go yes brands onto a concerted endpoints as.
As weve not disclosed that Mike.
Over Finfet.
That is knew there was there has to do with growth in new to recovery from synthetic.
What.
I'll try to thrive et cetera et cetera.
So to that.
But what we've done and which we.
We have also included when we say we are monitoring CEO protocol.
During the.
Statistical plan, we've also improved as the feedback.
Related to the diversity call points with the around.
Hello.
Physical methods.
Using on 80.
Well into additional on leases for descriptive assistance.
So thats what.
Between.
Okay got it and can you I guess just help us understand from a statistical perspective, you know measuring these changes like the composite of endpoint around changes a metabolic parameters, how that's going to be looked at relative to the histological and.
Point is it a hierarchical analysis are there are there any changes to I guess powering assumptions around potentially showing a benefit in fibrosis, just help us understand where these changes a metabolic parameters are going to fall relative to that other key secondary endpoints.
Yes. So we saw this change or is no no impact whatsoever on slated for the primary we regard to the offshore Brazil for most of the model you want to comment on that.
Well I take the most important point is that.
Of course the.
The statistical powering up the primary endpoint was not impacted whatsoever.
So for the key secondary endpoints, there's a day keeping approach that is in place and.
Once we hit on the primary ban we will be addressing both the fibrosis and the metabolic endpoint. So it's important that.
Both the fibrosis and the metabolic endpoints will be looked at as the key secondary endpoints.
Okay got it and just one one last question can you just talk a little bit about the pause phase one phase two studies and just help us understand which of these need to be completed prior to the NDA submission for Ela fiber north.
Sure you ought to take that.
Yes, so I.
Secondary or sorry, the phase two trials.
The issue there of course recorded is could patient recruitment, which has to be halted according to [noise].
Recommendation on guidelines from a regulatory agencies.
Further phase one trials of course as any program director from Phase one trials.
Throughout the course of the program there are several ongoing that were on going for for our program.
As it stands now they have to be put on hold as well and so once the kogut crosses over we will be looking to restart goes as soon as possible and there are a couple of those which are accurate needs to be done or.
We can submit for MBS submission and as you can understand there are some.
Our phase one trials, which does have to be done later on in the program just to give an example, Tom.
You consider that for the commercial.
Public.
There has to be some.
Adjustments made as any other program things taken or changing the colors and things like pack. So you do that do you need.
Bridging study and so on so that that's an example of a phase one which have to be started later on that program in which has to be completed before we can.
Submit for Andy.
Brian Brent Okay. Thanks, guys. Appreciate you taking the questions.
Thank you. Our next question is coming from Yasmeen Rahimi from Roth Capital Partners. Your line is our lives.
Hi team. Thank you for the update on the first question I have two years, just a clarification. The statistical modification I was just cut enclave does not does it doesn't affect.
Statistical preparation of one point improvement fibrosis, a biopsy recording that is a key secondary and then the second question for you is what will you presented topline I T T and per protocol population can you share without how you define the two to the extent to collect and I have a quick follow up.
[music].
Yes so.
Scientists needs.
The other type question, though there is no place.
Hello.
Right.
The definition of ours or the other point, where you have a key secondary on pluses that has listed.
Do you want to take three to them. So my question.
Yes for the ITC and per protocol definition.
The the recommendation to recent recommendations from the FDA does not impact that were whatsoever in place so.
As the client that since the beginning with the trial, so summit no impact on that whatsoever.
And then theme.
How can you comment on whether we will see also as it did I know you had a cohort of patients that were on ask why am I correct.
That going to be part of the total analysis, that's going to be presented at the top line as well.
Okay.
So yes.
The F. One cohort of course as an exploratory cohorts.
And we will be getting data from that cohorts.
As as topline analysis.
Okay. Thank you Tim.
Okay.
Thank you next question today is coming from my on front Army from B. Riley FBR. Your line is not alive.
Thanks, Dan for taking my questions and good afternoon, and good morning for success in the U.S.
So.
Clarification, the first but my question on the components of it the feedback to beyond the metabolic efficacy endpoints was safety also part of the dialogue, including maybe consideration of data from another in class agent and has there been at the SMB review and 2020.
And then the second back to that question was.
Have you looked at the baseline characteristics yet of what you'll see an resolve it and how that might.
Be in line or different relative to your expectations.
Hi, Mike Thanks for being so royalty.
In the year worker.
So.
Regarding CEO role.
Question about.
Safety and the question. If your question is low TV.
A discussion we'll see.
Yes.
On the CEO.
Keep in relation to keep it going improving.
Safety the answer is no, but I'm not clear like what was your question a Gregory sorry.
You're breaking up.
Yeah, I mean any anything.
Have you had a reason DSMB review for example, and obviously.
With the with the context of be Biotrue hours has has there any conversation than the with the agency on on safety.
Since you have engaged audiences utility.
Yes, so a lot less there's been very few was November 19, and 2020, we'll have one because every six months right. So we haven't had one in 2020.
But we will have one for six months of one downward movement.
Okay, and the based lender group, the owner as something to risk Dino Carol.
No I don't have much to add to that Mayank I think we have to realize that.
We had a very robust.
We had a very robust.
We had a very robust protocols in place both from the efficacy as well from a safety standpoint. Okay. So are there were no additional safety parameters, which were a request.
The FDA whatsoever, I think we have lot of bases covered from that from the safety standpoint.
In terms of the SMB of course, there may anchors as you know, it's every six months I suspect carriage of setting.
Considering what happened.
Hearing back at Us recommendation that the SMB hybrid or come continues despite a drug candidate betters generally well tolerated and no issues whatsoever. So their recommendation has been consistently to continuing to trial without any amendments are at each.
Change and that has been always been the case with Ella fried malaria throughout the different trials and I think you know with the ongoing trial and get to resolve it to your point My yanked. Their last one was I think 40, 42 months, which which is quite quite considerable. So so are we are very.
Comfortable.
Forward there, we should not have any issues, but you know.
I will tell but I think that's a very favorable.
Safety profile for Ela Fibermark.
And could you address that question on baseline characteristics have you looked at all sorry, yeah, well we booked.
Had.
Some look at at the baseline data so.
In terms of what's the baseline characteristics from a NAFLD activity score for example, as you know.
Comparing the resolve petrovic phase to be resolve it.
It does not have the problematic early stage Nash patients. So when you pick up Barker NAFLD activity score.
Baseline value is a little bit higher than what we saw interface to be.
Great and just.
On the European Agency dialogue is that also something you're you're hiring as you'd like you had with the FDA and if yes or what is the color on the timeline for that and how that might differ relative to what you may have heard from ft.
So like no fee.
The data there's been more focus is here with the FDA real quick.
You can do later we've.
With regards to development development in Europe.
Okay, great. Thanks for taking the questions.
Thank you next question is coming from ours from H.C. Wainwright. Your line is not line.
Hi, Thanks for taking my questions.
And glad to see that you now have a.
Very specific.
Our timeline for the result of data.
So I want to grow background on a couple of questions. If I may or that were asked earlier firstly.
Given that you've now receive feedback from the FDA on the secondary endpoints around.
Lippitt Lauren.
Could you comment at all and on on perhaps.
The perspective from the F.D.A. and how that may still be an important consideration in the overall risk benefit evaluation for Nash drugs.
Yeah.
Thanks for your question.
I really cannot come up.
On that.
I cannot particularly since the acquisition and we should we should be down discussing for years the content of our decision I think right now.
The discussion industries orphans divestitures, the will be premature.
On this because basically asking us to merchandise later stage.
Okay.
But just to add to that Ed I think.
Important that are the key stakeholders.
In the Nash space.
I realize the importance of the metabolic aspect of Nash patients.
I mean globally.
Last just consider as deliver manifestation of metabolic diseases and with pattern mine.
Whether it's the regulatory agencies or to key opinion leaders real experts and the Nashville.
Realized that for the management for Nash patients.
Considering their metabolic state is gonna be very important, especially keeping in mind that they're leading cause of mortality.
Nash patients cardiovascular events license.
In other key spread quarters are cognizant of that and I think following the metabolic parameters and if a.
Greg is able to have a positive impact on that I think that it's going to be something that's going to be.
Pardon.
To track and very important clinical management applications and of course to health care providers.
We'd be looking at to that and taking that into account when do you think about how they want to.
Yes, and managed care patients from a holistic point of view.
And the Mrs. Carol I'll I'll go ahead, and add to that and just acknowledging the comprehensive care patients with Nash. Many itself has associated metabolic conditions, and certainly metabolic parameters, such as let bids and changes in.
Workers parameters are critical in terms of optimizing the care at these patients and so certainly that data read out from resolve that well be at driver for Gen sets in terms of ongoing and future discussions with apps DNA.
When we prepare our and Diego CH and ideally of course, we would like to be able to elevate the extent to which we can include these data in the label of course, we not engaged in those discussions at this point in time that will clearly be a repeatable item at the time that we engage with.
FDA during that radiotherapy and the process.
Okay, great. Thanks for that additional detail.
Then just a follow up.
How long will these additional and da required phase one studies take and is this the driver behind pushing back the NDA submission timeline to.
The first half of 21.
And our other than these phase one studies are there any other requirements that are our gating factors to the submission.
Thank you.
So I read an article we commenced on the exact time those those studies are usually central cities and also the ongoing facing uptake we have two on south from from scratch.
You can just sort of from and resume when we left the yet but.
They are CEO, so on the critical path.
Yes, the hiring and there's a reason why are we at least.
On to the first half were 2021.
Or your training now the reason why it's very difficult to gear see any.
More precise guidance is because it obviously depends on fee the name of the couldn't make and then make which obviously Ireland continuously.
As a clear at this point our home.
Okay. So when we said we were kind of thinking you know you know head.
Although the take this time during which is the rewards compliance and partly as a month to add because we don't expect.
It's tied to be able to kind of presumably that makes days. They will obviously be some some sort of disruption.
Taken in humans enough time to sort of get back.
I can get fees.
And then we were thinking and again no formal debt and just sort of working you floor of Clubcorp that we were thinking maybe it's a quarter or two quarters based on the fact that in China.
It would appear to ethanol that theres nothing yet in response to that could cause us letrozole also process.
I will tell if you want to our provides more detail.
Right I think in light of Covance, certainly I think we all wish we had a crystal ball in terms of better understanding that magnitude of that packs for clinical development programs such as for our fiber in or I think the good news for our phase one program.
And the studies that are necessary for the FDA submission is that these studies are being conducted and healthy individuals and so our ability to we initiate these phase one studies I think the bar in some ways, there's a little bit lower than when we give consideration chip for exam.
Well the start of our PBC study, who are in that study being conducted obviously in individuals with a chronic liver condition that may put them at greater risk for combat 19 infection complications. So I think we're going to be following closely with our study site.
Many of which have closed down because of the cobot ramp related situation and so we're monitoring the situation very closely with the intention being that won't be placed two we initiate as soon as we have a higher level of certainty in terms of the evolution of the code at 19 crisis.
Okay, great understood. Thank you again for your our response.
Sure.
Thank you. Our final question today is coming from zones Roquefort from Bryan Garnier Your line is alive.
Okay. Good afternoon. Thank you for taking my question so.
The first one is the or so on the timing.
Freezing the hiring so assuming let's make sure what is actually no more situation for clinical trials.
Comes back in let's say doing just some rural early September.
What does that mean in terms of H., one prince between two one hiding does it mean needles.
The first harmful by the end. So this is my first question, but perhaps early easier so some issues.
And and the second one is do you anticipate.
And the Advisory Committee following the end da hiding thank you.
Hi, how fast can control question look I mean, it's not going forward to unfold, but it's really difficult to want to say to be mostly size.
No.
Those types of of 21, because there's so much.
And like you said, it's it causes 19.
Situation.
Which is the first uncertainty there is also how quickly.
Growth is different sized that back of the affiliates, which which is another unknowns that but we do not come forth and.
Just so really no.
Really I don't want to be.
Multi side than on each one because.
I can do geography, which ends of the mall.
In terms of for.
Please proceed easiest outcome.
To truly.
Too early to say, a result of and formation or there will be a netcomm.
Fall fall things like that we'll see.
What will discuss sales growth.
So will come from.
Again at this point our result more.
Okay, and if I mean, a quick find on sure one.
Regarding the marketing and sitting in Gen expenses since it has increased significantly in 19.
And because it was sort of short delay.
Filing approval and launch also.
You know do.
Do you do we have to anticipate takes the same later in <unk> expenses for these two or two lines are in Twentytwenty was this year or should these two lines declined a bit speakers, rather sort of DNA incur launch dates will elaborate on.
No well first of all you're right. It is increased essentially.
In key because we did a lot of work or on the research market research.
It's also a site that we hired.
No those.
Folks on board directly.
Or is.
Let's now review these competencies ethanol and RFP, we saw we've approached them and the.
The level of 54, we hire for both will of course, you know people thought so all of that contributed to that the increase in talks about it sounds that 2020, I think we've said in.
The preliminary remarks, it really depends on fee, we believe it or we don't each result, so right now we are pleased with us.
The full speed ahead in terms of preparation and launch readiness.
And then after the we did see every both we don't just accordingly.
Okay. Many thanks for everything.
Great. So sorry for free for your questions and just before you leave I just Wonder reminder.
All the French speaking audience that this [noise].
This call will be translated and script intend to French so pretty circuit for that on a per tuners our GRC.
I don't see Funko fund or just over the.
So call that strategy on how say to screw Fred this premium searcher Super messy.
Thank you contract.
Thank you we reach into the question answer session I'd like to turn the floor back over to management for any further or closing comments.
Okay. Thank you everyone for joining so I realized that we generated to take over questions, but of course fee management will be happy to make themselves available to take care.
Several question on I'm wondering one meeting.
These include I would say that I'm very proud of what you're going to team has delivered across an old forgone really pasture, we're well positioned to build them. This momentum in 2020.
It varies a great deal to look forward to this year.
We are committed to clear strategy for success and you will be very gratifying to ever Mexico President. The interesting results are very focused steady. Thank you very much.
Thanks for that does conclude todays teleconference. You may disconnect your lines as time and have a wonderful day. We thank you for your participation today.